One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Hit hard and remove treatment – this treatment strategy in Hodgkin Lymphoma promises less fatigue and less sick-leave
doi : 10.1016/j.annonc.2024.01.004
Volume 35, Issue 3, March 2024, Pages 245-247
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease☆
doi : 10.1016/j.annonc.2023.11.015
Volume 35, Issue 3, March 2024, Pages 248-266
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
doi : 10.1016/j.annonc.2023.12.007
Volume 35, Issue 3, March 2024, Pages 267-275
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial☆
doi : 10.1016/j.annonc.2023.11.014
Volume 35, Issue 3, March 2024, Pages 276-284
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer
doi : 10.1016/j.annonc.2023.11.017
Volume 35, Issue 3, March 2024, Pages 285-292
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial☆
doi : 10.1016/j.annonc.2023.11.018
Volume 35, Issue 3, March 2024, Pages 293-301
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)☆
doi : 10.1016/j.annonc.2023.12.001
Volume 35, Issue 3, March 2024, Pages 302-307
European cancer mortality predictions for the year 2024 with focus on colorectal cancer
doi : 10.1016/j.annonc.2023.12.003
Volume 35, Issue 3, March 2024, Pages 308-316
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
doi : 10.1016/j.annonc.2023.11.013
Volume 35, Issue 3, March 2024, Pages 317-326
Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Letter to the Editor regarding ‘Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study’ by Moik F, Riedl JM, and Ay C
doi : 10.1016/j.annonc.2023.11.012
Volume 35, Issue 3, March 2024, Pages 328-329
Letter to the editor regarding ‘Misclassified confounders in the second interim analysis of the MAGNITUDE trial’ by P. Chen, M. Liu, G.Y. Li, F. Sun, T. Li
doi : 10.1016/j.annonc.2023.12.002
Volume 35, Issue 3, March 2024, Pages 329-330
Caution against overoptimistic findings
doi : 10.1016/j.annonc.2023.10.795
Volume 35, Issue 3, March 2024, Pages 330-331
VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)
doi : 10.1016/j.annonc.2024.01.005
Volume 35, Issue 3, March 2024, Pages 332-333
